Showing results (191-200 of 258) with videos related to
Sort By:
Pageof 26
Molecular and Cellular Biology|May 28, 2009
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen speciesSunil Sudarshan, Carole Sourbier, Hye-Sik Kong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.Immunity|June 14, 2008
The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradationAvital Lev, Kazuyo Takeda, Damien Zanker, et al.Plos One|March 6, 2008
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential targetMariëlle I Gallegos Ruiz, Karijn Floor, Paul Roepman, et al.Oncogene|March 1, 2005
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cellsFederico A Steiner, Julie A Hong, Maria R Fischette, et al.Journal of Clinical Pharmacology|August 28, 2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancerAndrew K L Goey, Tristan M Sissung, Cody J Peer, et al.Cancer Chemotherapy and Pharmacology|February 14, 2013
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomasSook Ryun Park, Giovanna Speranza, Richard Piekarz, et al.Oncotarget|January 7, 2017
Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunityMikako Ogawa, Yusuke Tomita, Yuko Nakamura, et al.Blood|December 21, 2006
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasIvana Gojo, Anchalee Jiemjit, Jane B Trepel, et al.Clinical Medicine Insights. Oncology|November 15, 2016
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.Pageof 26